InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,127.79
(
1.26%
)
US TECH 100
17,446.00
(
2.17%
)
Dow Jones
38,675.68
(
1.18%
)
Brent Oil
83.26
(
0.59%
)
Bitcoin
63,806.65
(
-0.13%
)
Post# of 1509
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Bertsllc

Send PM Follow Ignore
Followers 314
Posts 24877
Boards Moderated 9
Alias Born 10/26/2008

Bertsllc

Member Level

Re: None

Friday, 05/13/2016 8:01:43 AM

Friday, May 13, 2016 8:01:43 AM

Post# of 1509
BERKELEY HEIGHTS, N.J., May 13, 2016 (GLOBE NEWSWIRE) -- Edge Therapeutics, Inc. (EDGE), a clinical-stage biotechnology company developing novel hospital-based therapies for the management of acute, life-threatening conditions, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its investigational product EG-1962 for the treatment of subarachnoid hemorrhage (SAH).

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up